Multicenter phase II study of brequinar sodium in patients with advanced breast cancer
In this study, 34 patients with advanced breast cancer were treated with brequinar sodium: 75% of the patients were postmenopausal, and 94% had received chemotherapy previously; 50% had previously received an anthracycline-containing regimen. Brequinar was administered intravenously at a median week...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical oncology 1993-12, Vol.16 (6), p.526-528 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 528 |
|---|---|
| container_issue | 6 |
| container_start_page | 526 |
| container_title | American journal of clinical oncology |
| container_volume | 16 |
| creator | CODY, R STEWART, D DEFORNI, M MOORE, M DALLAIRE, B AZARNIA, N GYVES, J |
| description | In this study, 34 patients with advanced breast cancer were treated with brequinar sodium: 75% of the patients were postmenopausal, and 94% had received chemotherapy previously; 50% had previously received an anthracycline-containing regimen. Brequinar was administered intravenously at a median weekly dose of 1,200 mg/m2. The toxicity was moderate, with 17 patients (50%) experiencing grade 3 or 4 toxicity. There were 33 patients evaluable for response: 4 patients (12%; 95% confidence interval, 3.4-28.2%) achieved partial responses, 10 patients (30%) were stable, and 19 patients (58%) had progressive disease. We conclude that, at this dose and schedule, brequinar has only modest activity in patients with advanced breast cancer. |
| doi_str_mv | 10.1097/00000421-199312000-00014 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00000421_199312000_00014</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>8256771</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-f21ce9e0dbf22902a16136ce465fad72bfcc27c4e571ab403e280810396117923</originalsourceid><addsrcrecordid>eNo9kFtLAzEQhYMotVZ_gpAHX1czmc1m8yjipVDxRcW3JZsLjbTbNdlV-u_dtbUDw3CYcwbmI4QCuwam5A0bK-eQgVIIfBDZ0JAfkSkIlFku8OOYTBmXMkOJ_JScpfQ5WETB5IRMSi4KKWFK3p_7VReMazoXabvUydH5nKaut1u68bSO7qsPjY40bWzo1zQ0tNVdGPyJ_oRuSbX91o1xdrTq1FEzqnhOTrxeJXexnzPy9nD_eveULV4e53e3i8wgqi7zHIxTjtnac64Y11AAFsblhfDaSl57Y7g0uRMSdJ0zdLxkJTBUBYBUHGek3N01cZNSdL5qY1jruK2AVSOp6p9UdSBV_ZEaope7aNvXa2cPwT2aYX-13-tk9MrH4bGQDjYshcQc8Bfj-HCN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Multicenter phase II study of brequinar sodium in patients with advanced breast cancer</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>CODY, R ; STEWART, D ; DEFORNI, M ; MOORE, M ; DALLAIRE, B ; AZARNIA, N ; GYVES, J</creator><creatorcontrib>CODY, R ; STEWART, D ; DEFORNI, M ; MOORE, M ; DALLAIRE, B ; AZARNIA, N ; GYVES, J</creatorcontrib><description>In this study, 34 patients with advanced breast cancer were treated with brequinar sodium: 75% of the patients were postmenopausal, and 94% had received chemotherapy previously; 50% had previously received an anthracycline-containing regimen. Brequinar was administered intravenously at a median weekly dose of 1,200 mg/m2. The toxicity was moderate, with 17 patients (50%) experiencing grade 3 or 4 toxicity. There were 33 patients evaluable for response: 4 patients (12%; 95% confidence interval, 3.4-28.2%) achieved partial responses, 10 patients (30%) were stable, and 19 patients (58%) had progressive disease. We conclude that, at this dose and schedule, brequinar has only modest activity in patients with advanced breast cancer.</description><identifier>ISSN: 0277-3732</identifier><identifier>EISSN: 1537-453X</identifier><identifier>DOI: 10.1097/00000421-199312000-00014</identifier><identifier>PMID: 8256771</identifier><identifier>CODEN: AJCODI</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Biphenyl Compounds - therapeutic use ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Chemotherapy ; Female ; Humans ; Medical sciences ; Middle Aged ; Neoplasm Metastasis ; Pharmacology. Drug treatments</subject><ispartof>American journal of clinical oncology, 1993-12, Vol.16 (6), p.526-528</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-f21ce9e0dbf22902a16136ce465fad72bfcc27c4e571ab403e280810396117923</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3857341$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8256771$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CODY, R</creatorcontrib><creatorcontrib>STEWART, D</creatorcontrib><creatorcontrib>DEFORNI, M</creatorcontrib><creatorcontrib>MOORE, M</creatorcontrib><creatorcontrib>DALLAIRE, B</creatorcontrib><creatorcontrib>AZARNIA, N</creatorcontrib><creatorcontrib>GYVES, J</creatorcontrib><title>Multicenter phase II study of brequinar sodium in patients with advanced breast cancer</title><title>American journal of clinical oncology</title><addtitle>Am J Clin Oncol</addtitle><description>In this study, 34 patients with advanced breast cancer were treated with brequinar sodium: 75% of the patients were postmenopausal, and 94% had received chemotherapy previously; 50% had previously received an anthracycline-containing regimen. Brequinar was administered intravenously at a median weekly dose of 1,200 mg/m2. The toxicity was moderate, with 17 patients (50%) experiencing grade 3 or 4 toxicity. There were 33 patients evaluable for response: 4 patients (12%; 95% confidence interval, 3.4-28.2%) achieved partial responses, 10 patients (30%) were stable, and 19 patients (58%) had progressive disease. We conclude that, at this dose and schedule, brequinar has only modest activity in patients with advanced breast cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biphenyl Compounds - therapeutic use</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Chemotherapy</subject><subject>Female</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Pharmacology. Drug treatments</subject><issn>0277-3732</issn><issn>1537-453X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kFtLAzEQhYMotVZ_gpAHX1czmc1m8yjipVDxRcW3JZsLjbTbNdlV-u_dtbUDw3CYcwbmI4QCuwam5A0bK-eQgVIIfBDZ0JAfkSkIlFku8OOYTBmXMkOJ_JScpfQ5WETB5IRMSi4KKWFK3p_7VReMazoXabvUydH5nKaut1u68bSO7qsPjY40bWzo1zQ0tNVdGPyJ_oRuSbX91o1xdrTq1FEzqnhOTrxeJXexnzPy9nD_eveULV4e53e3i8wgqi7zHIxTjtnac64Y11AAFsblhfDaSl57Y7g0uRMSdJ0zdLxkJTBUBYBUHGek3N01cZNSdL5qY1jruK2AVSOp6p9UdSBV_ZEaope7aNvXa2cPwT2aYX-13-tk9MrH4bGQDjYshcQc8Bfj-HCN</recordid><startdate>19931201</startdate><enddate>19931201</enddate><creator>CODY, R</creator><creator>STEWART, D</creator><creator>DEFORNI, M</creator><creator>MOORE, M</creator><creator>DALLAIRE, B</creator><creator>AZARNIA, N</creator><creator>GYVES, J</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19931201</creationdate><title>Multicenter phase II study of brequinar sodium in patients with advanced breast cancer</title><author>CODY, R ; STEWART, D ; DEFORNI, M ; MOORE, M ; DALLAIRE, B ; AZARNIA, N ; GYVES, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-f21ce9e0dbf22902a16136ce465fad72bfcc27c4e571ab403e280810396117923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biphenyl Compounds - therapeutic use</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Chemotherapy</topic><topic>Female</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CODY, R</creatorcontrib><creatorcontrib>STEWART, D</creatorcontrib><creatorcontrib>DEFORNI, M</creatorcontrib><creatorcontrib>MOORE, M</creatorcontrib><creatorcontrib>DALLAIRE, B</creatorcontrib><creatorcontrib>AZARNIA, N</creatorcontrib><creatorcontrib>GYVES, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>American journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CODY, R</au><au>STEWART, D</au><au>DEFORNI, M</au><au>MOORE, M</au><au>DALLAIRE, B</au><au>AZARNIA, N</au><au>GYVES, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multicenter phase II study of brequinar sodium in patients with advanced breast cancer</atitle><jtitle>American journal of clinical oncology</jtitle><addtitle>Am J Clin Oncol</addtitle><date>1993-12-01</date><risdate>1993</risdate><volume>16</volume><issue>6</issue><spage>526</spage><epage>528</epage><pages>526-528</pages><issn>0277-3732</issn><eissn>1537-453X</eissn><coden>AJCODI</coden><abstract>In this study, 34 patients with advanced breast cancer were treated with brequinar sodium: 75% of the patients were postmenopausal, and 94% had received chemotherapy previously; 50% had previously received an anthracycline-containing regimen. Brequinar was administered intravenously at a median weekly dose of 1,200 mg/m2. The toxicity was moderate, with 17 patients (50%) experiencing grade 3 or 4 toxicity. There were 33 patients evaluable for response: 4 patients (12%; 95% confidence interval, 3.4-28.2%) achieved partial responses, 10 patients (30%) were stable, and 19 patients (58%) had progressive disease. We conclude that, at this dose and schedule, brequinar has only modest activity in patients with advanced breast cancer.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>8256771</pmid><doi>10.1097/00000421-199312000-00014</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-3732 |
| ispartof | American journal of clinical oncology, 1993-12, Vol.16 (6), p.526-528 |
| issn | 0277-3732 1537-453X |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00000421_199312000_00014 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Aged Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Biphenyl Compounds - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - pathology Chemotherapy Female Humans Medical sciences Middle Aged Neoplasm Metastasis Pharmacology. Drug treatments |
| title | Multicenter phase II study of brequinar sodium in patients with advanced breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T14%3A31%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multicenter%20phase%20II%20study%20of%20brequinar%20sodium%20in%20patients%20with%20advanced%20breast%20cancer&rft.jtitle=American%20journal%20of%20clinical%20oncology&rft.au=CODY,%20R&rft.date=1993-12-01&rft.volume=16&rft.issue=6&rft.spage=526&rft.epage=528&rft.pages=526-528&rft.issn=0277-3732&rft.eissn=1537-453X&rft.coden=AJCODI&rft_id=info:doi/10.1097/00000421-199312000-00014&rft_dat=%3Cpubmed_cross%3E8256771%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8256771&rfr_iscdi=true |